Business
These biotech stocks are getting hammered by shocking brittle-bone treatment study results
SOURCE:MarketWatch|BY:Tomi Kilgore
Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.
Failed to fetch content: Request failed with error code 401